221 results on '"Holubec L"'
Search Results
2. The role of ABC transporters in progression and clinical outcome of colorectal cancer
3. 1405P Survival of patients with non-small cell lung cancer and exon 20 insertion mutation from the Czech Republic
4. The evaluation of tumor markers and their impact on prognosis in gallbladder, bile duct, and cholangiocellular carcinomas – A pilot study
5. C20 Selected molecular markers of tumour tissue and their use in predicting the efficacy of targeted therapy of metastatic renal cell carcinoma
6. Use of faecal markers in screening for colorectal neoplasia: A European group on tumor markers (EGTM) position paper
7. Preoperative tumor markers as prognostic factors of colorectal liver metastases
8. Expression of mRNA MMP-7 and mRNA TIMP-1 in non-small cell lung cancer
9. Prognostic importance of thymidine kinase in colorectal and breast cancer
10. [Prognostic factors of early recurrence of colorectal liver metastases and their usage in clinical praxis]
11. [A partial relaps of a colorectal carcinoma metastatic process following liver surgery--a multifactorical study]
12. Klasifikace nádorů centrálního nervového systému - WHO 2016 Update.
13. Quantitative estimation of matrix metalloproteinases 2 and 7 (MMP-2, MMP-7) and tissue inhibitors of matrix metalloproteinases 1 and 2 (TIMP-1, TIMP-2) in colorectal carcinoma tissue samples
14. [Serum tumor markers at exocrine adenocarcinoma of pancreas]
15. [Metabolic syndrome and latent depression in the population sample]
16. [The role of procalcitonin in the patient assessment after surgical procedures]
17. Treatment Satisfaction, Symptom Control, and Quality of Life (Qol) with Lanreotide Autogel (Lan) in Neuroendocrine Tumour (Net) Patients with Carcinoid Syndrome (Cs): Results from the Symnet Study
18. The significance of CEA, CA19-9 and CA72-4 in the detection of colorectal carcinoma recurrence
19. Use of faecal markers in screening for colorectal neoplasia: a European group on tumor markers position paper
20. P114 The clinical experience with cabazitaxel application in the 2nd line of castration-resistant prostate cancer treatment
21. P054 The importance of biomarkers in localised prostate cancer diagnostics
22. Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update
23. The Difference in the Serum Levels of BDNF, IL-6, IL-8, IL-10 and EGF in Oncology Patients Divided According to the Presence of Symptoms of Depression
24. 6021 POSTER The Role of ABC Transporter Genes in Colorectal Cancer Resistance
25. PSY29 DARBEPOETIN ALFA VERSUS EPOETIN ALFA FOR TREATMENT OF CHEMOTHERAPY-INDUCED ANEMIA:A HEALTH ECONOMIC EVALUATION
26. UP-1.125: Importance of miRNAs Expression in Prostate Cancer and Benign Prostate Tissue
27. UP-1.124: Chromogranin A in Hormone Independent Prostate Cancer
28. UP-1.123: Expression of Dd3/Pca3 mRNA in Tissue at Patients with Prostate Cancer and Benign Prostate Hyperplasia
29. UP.78: Dd3/Pca3 (Differential Display Code 3) in Prostate Cancer Diagnosis: Experience From Czech Republic
30. P016 PREDICTIVE VALUE OF PROCALCITONIN AND CYTOKINES IN ERCP INDUCED ACUTE PANCREATITIS
31. MP-11.10: DD3/PCA3 (differential display code 3) in prostate cancer diagnosis – first data from Czech Republic
32. Význam časné nádorové regrese a hloubky léčebné odpovědi při hodnocení účinnosti systémové léčby metas ta zujícího kolorektálního karcinomu.
33. The effect of oral vinorelbine and capecitabine in patients with metastatic breast cancer
34. Folate co-administration improves the effectiveness of fenofibrate to decrease the lipoprotein oxidation and endothelial dysfunction surrogates
35. The clinical significance of the follow up of tumor markers in breast carcinoma
36. W12-P-039 The influence of folate supplementation on oxidative modification of lipoproteins in normohocysteinemic patients with hypercholesterolemia
37. PROCALCITONIN AS A MARKER OF POST- OPERATIVE FOLLOW UP AND COMPLICATION OF CARDIAC SURGERY
38. 1134PD - Treatment Satisfaction, Symptom Control, and Quality of Life (Qol) with Lanreotide Autogel (Lan) in Neuroendocrine Tumour (Net) Patients with Carcinoid Syndrome (Cs): Results from the Symnet Study
39. Chylózní ascites jako závažná komplikace neuroendokrinního tumoru ilea - kazuistika.
40. Léčba polyneuropatické bolesti u nemocného s generalizovaným, kastračně rezistentním karcinomem prostaty - klinická kazuistika.
41. 1464P - The Difference in the Serum Levels of BDNF, IL-6, IL-8, IL-10 and EGF in Oncology Patients Divided According to the Presence of Symptoms of Depression
42. Clinicopathological assessment and quantitative estimation of the matrix metalloproteinases MMP-2 and MMP-7 and the inhibitors TIMP-1 and TIMP-2 in colorectal carcinoma tissue samples
43. M.586 The influence of high-normal thyreostimulating hormone and subclinical hypothyroidism on risk profile of patients with manifest coronary heart disease
44. The importance of prognostic factors in premenopausal women with breast cancer
45. MONOTOTAL - PROGNOSIS AND THERAPY CONTROL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER
46. Significance of the TPS cytokeratin marker in the postoperative follow up of colorectal carcinoma patients | Význam cytokeratinového markeru TPS v pooperacním sledováiní nemocných s kolorektálním karcinomem
47. PROGNOSTIC SIGNIFICANCE OF miR-21 AND miR-143 EXPRESSION IN TISSUE SAMPLES OF COLORECTAL CARCINOMA AND COLORECTAL LIVER METASTASES
48. Changes of thymidine kinase (TK) during adjuvant and palliative chemotherapy
49. MONOTOTAL-MARKER FOR NON-SMALL CELL LUNG CARCINOMA (NSCLC)
50. Infiltration of colorectal carcinoma by S100 + dendritic cells and CD57 + lymphocytes as independent prognostic factors after radical surgical treatment
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.